Browse > Article
http://dx.doi.org/10.7742/jksr.2019.13.3.359

Effect of Simultaneous Use of Platelet Glycoprotein IIb / IIIa Receptor Blocker and Thrombus Aspiration in Patients with Coronary Artery Stent Thrombosis  

Kim, In Soo (Department of Radiology, Dongshin University)
Choi, Nam Gil (Department of Radiology, Dongshin University)
Kong, Chang gi (Department of Radiology, Dongshin University)
Eun, Sung jong (Department of Radiology, Hanlyo University)
Han, Jae Bok (Department of Radiology, Dongshin University)
Publication Information
Journal of the Korean Society of Radiology / v.13, no.3, 2019 , pp. 359-369 More about this Journal
Abstract
To evaluate the effect of simultaneous use of platelet glycoprotein IIb / IIIa receptor blocker and catheter assisted thrombus aspiration in the treatment of coronary stent thrombosis. 267 patients ($64.6{\pm}12.1years$, 187 men) with stent thrombosis on coronary angiography at Chonnam National University Hospital from July 2008 to July 2017 were enrolled. We devided two groups based on treatment modalities: Group I (N=32, platelet glycoprotein IIb / IIIa receptor blocker and thrombo-aspiration), Group II (N =235, either platelet glycoprotein IIb /IIIa receptor blocker or thrombo-aspiration, or none of both), and the major cardiac events including death, revascularization and stent thrombosis were followed up for 1 year. There were no significant differences in clinical characteristics between the two groups including age (Group I: $60.8{\pm}12.9$ vs. Group II: $65.1{\pm}11.9$, p= 0.603), male (Group I: 75.0% vs. Group II: 69.4%, p=0.681), and left ventricular ejection fraction (Group I: $58.1{\pm}9.0%$ vs. Group II: $59.5{\pm}11.9%$, p= 0.127). The major cardiac events did not differ between the two groups (Group I: 12.5% vs. Group II: 23.8%, p=0.180). The secondary endopoints were as followings: The mortality rate (Group I: 0% vs. 13.2%, Group II: p=0.034), target lesion revascularization (Group I: 9.4% vs Group II: 6.4%, p=0.461) and stent thrombosis (Group I: 3.1% vs. Group II: 4.7%, p=1.000). In conclusion, in the treatment of coronary artery stent thrombosis, simultaneous use of platelet glycoprotein IIb / IIIa receptor blocker and thrombus aspiration was associated with better clinical outcomes regarding 1 year mortality.
Keywords
Stent thrombosis; Major cardiac events; Thrombus aspiration; Platelet glycoprotein IIb / IIIa receptor blocker;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, "Analysis of 1-year clinical outcomes in the SIRIUS trial: randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis," Circulation, Vol. 109, No. 5, pp. 634-640, 2004.   DOI
2 Salam AM, Al Suwaidi J, Holmes DR Jr, "Drug-eluting coronary stents," Curr Probl Cardiol, Vol. 31, No. 1, pp. 8-119, 2006.   DOI
3 Stone GW, Maehara A, Witzenbichler B, "Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial," JAMA, Vol. 307, No. 17, pp. 1817-1826, 2012.   DOI
4 De Luca G, Navarese EP, Suryapranata H, "A meta-analytic overview of thrombectomy during primary angioplasty," Int J Cardiol, Vol. 166, No. 3, pp. 606-612, 2013.   DOI
5 S. Park, G. R. Hong, H. S. Seo, S. J. Tahk, "Stent thrombosis after successful drug-eluting stent implantation," Korean Circ J, Vol. 35, No. 2, pp. 163-71, 2005.   DOI
6 Leon MB, Bakhai A, "Drug-eluting stents and glycoprotein IIb/III inhibitors: combination therapy for the future," Am Heart J, Vol. 146(4 Suppl), S13-7, 2003.   DOI
7 Jeremias A, Sylvia B, Bridges J, "Stent thrombosis after successful sirolimus-eluting stent implantation," Circulation, Vol. 109, No. 16, pp. 1930-1932, 2004.   DOI
8 D. W. Park, S. W. Park, "Stent thrombosis in the era of the drug-eluting stent," Korean Circ J, Vol. 35, No. 2, pp. 791-794, 2005.   DOI
9 Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, et al. "Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project," J Am Coll Cardiol, Vol. 47, No. 1, pp. 175-181, 2006.   DOI
10 Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, "Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)," Lancet, Vol. 352, No. 9129, pp. 673-681, 1998.   DOI
11 Burzotta F, Romagnoli E, Manzoli A, "The Outcome of PCI for stent-Thrombosis Multicentre Study (OPTIMIST) : rationale and design of a multicenter registry," Am Heart J, Vol. 153, No. 3, pp. 377. e1-5, 2007.   DOI
12 Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Sings and Symptoms (PRISM-PLUS) Study Investigators, "Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction," N Engl J Med, Vol. 338, No. 21, pp. 1488-1497, 1998.   DOI
13 Khan MM, Ellis SG, Aguirre FV, Weisman HF, Wildermann NM, Califf RM, Topol EJ, Kleiman NS, "Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications," Am J Cardiol, Vol. 31, No. 1, pp. 31-36, 1998.
14 Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ, "Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade," Am J Cardiol, Vol. 82, No. 1, pp. 7-12, 1998.   DOI
15 CAPTURE (C7E3 Fab AntiPlatelet Therapy in Unstable Refractory angina) Investigators, "Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina," Lancet, Vol. 349, No. 963, pp. 1429-1435, 1997.   DOI
16 D. S. Sim, M. H. Jeong, J. C. Kang, "Clinical outcome in elderly patients older than 70years with acute myocardial infarction after use of platelet glycoprotein IIb/IIIa receptor blocker during percutaneous coronary intervention," Korean Journal of Internal Medicine, Vol. 67, No. 6, pp. 580-588, 2004.
17 Frobert O, Lagerqvist B, Gudnason T, "Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial): a multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish Angiography and Angioplasty Registry (SCAAR) platform: study design and rationale," Am Heart J, Vol. 160, No. 6, pp. 1042-1048, 2010.   DOI
18 Farb A, Boam AB, "Stent thrombosis redux: the FDA perspective," N Engl J Med, Vol. 356, No. 10, pp. 984-987, 2007.   DOI
19 Daemen J, Wenaweser P, Tsuchida K, "Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study," Lancet, Vol. 369, No. 9562, pp. 667-678, 2007.   DOI
20 I. S. Kim, M. H. Jeong, S. J. Jang, J. B. Han, and Y. I. Jang, "Clinical Outcomes of Stent Thrombosis after Drug-Eluting Coronary Stent Implantation," The Korea Contents Association, Vol. 13, No. 12, pp. 880-892, 2013.   DOI
21 Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM, "Specific platelet mediators and unstable coronary artery lesions," Circulation, Vol. 80, No. 1, pp. 198-205, 1989.   DOI
22 Steven P. Marso, A. Michael Lincoff, Stephen G. Ellis, Deepak L. Bhatt, Jean-Francois Tanguay, Neal S. Kleiman, Talal Hammoud, Joan E. Booth, Shelly K. Sapp, and Eric J. Topol, "Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes Mellitus : Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) Diabetic Substudy," Circulation, Vol. 100, No. 25, pp. 2477-2484, 1999.   DOI
23 Lipiecki J, Monzy S, Durel N, "Effect of thrombus aspiration on infarct size and left ventricular function in highrisk patients with acute myocardial infarction treated by percutaneous coronary intervention: results of a prospective controlled pilot study," Am Heart J, Vol. 157, No. 3, pp. 583. e1-7, 2009.   DOI
24 Haeck JD, Koch KT, Bilodeau L, "Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-Elevation) study," JACC Cardiovasc Interv, Vol. 2, No. 10, pp. 934-943, 2009.   DOI
25 Svilaas T, Vlaar PJ, van der Horst IC, "Thrombus aspiration during primary percutaneous coronary intervention," N Engl J Med, Vol. 358, No. 6, pp. 557-567, 2008.   DOI
26 Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K, "Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor," Am Heart J, Vol. 130, No. 4, pp. 877-892, 1995.   DOI
27 Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS, "Inhibition of platelet-medicaated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment an acute thrombosis and clinical restenosis," J Clin Invest, Vol. 98, No. 3, pp. 863-874, 1996.   DOI
28 Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, "Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months," Lancet, Vol. 343, No. 8902, pp. 881-886, 1994.   DOI
29 Cura FA, Bhatt DL, Lincoff AM, Kapadia SR, L'Allier PL, Ziada KM, Wolski KE, Moliterno DJ, Brener SJ, Ellis SG, Topol EJ, "Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions," Circulation, Vol. 102, No. 1, pp. 28-34, 2000.   DOI
30 Coleman KR, Braden GA, Willingham MC, Sane DC, "Vitaxin, a humanized monoclonal antibody to the vitronectin receptor, reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits," Circ Res., Vol. 84, No. 11, pp. 1268-1276, 1999.   DOI